Recombinant myxoma viruses and uses thereof
AssigneesSystems Oncology, LLC, MUSC Foundation for Research Development
InventorsJeff KIEFER, Ramon MORENO, Spyro MOUSSES, Eric BARTEE
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a recombinant oncolytic virus engineered to express a soluble form of an immune checkpoint protein. In certain aspects, the oncolytic vims is a replication competent virus such as myxoma vims. Methods of cancer treatment comprising administering the recombinant oncolytic virus expressing the soluble form of the immune checkpoint protein are also provided.
Claims95
A recombinant oncolytic virus comprising one or more expression cassettes encoding (a) a soluble form of programmed cell death protein 1 (PD1), and (b) interleukin 12 (IL-12) or interleukin 2 (IL-2), wherein the virus is replication competent.
A recombinant oncolytic virus comprising one or more expression cassettes encoding a mutant soluble form of PD1 (mutPD1) and optionally interleukin 12 (IL-12) or interleukin 2 (IL-2), wherein the virus is replication competent and wherein the mutPD1 prevents recognition of mutPD1 by an anti-PD1 antibody.
The method of claim 55, wherein the antibody is Pembrolizumab.
A recombinant oncolytic virus comprising one or more expression cassettes encoding a soluble form of T-cell immunoglobulin and mucin-domain containing-3 (TIM3).
The oncolytic virus of claim 60, wherein the one or more viral promoters is/are synthetic early/late poxvirus promoter.
The method of claim 74, wherein the cancer is melanoma, kidney cancer, colorectal cancer, breast cancer, lung cancer, head and neck cancer, brain cancer, leukemia, prostate cancer, bladder cancer, and ovarian cancer.
The method of claim 90, wherein the cancer is melanoma, kidney cancer, colorectal cancer, breast cancer, lung cancer, head and neck cancer, brain cancer, leukemia, prostate cancer, bladder cancer, and ovarian cancer.
Dependencies are inferred from the claim text.